Isturisa (Osilodrostat)

Osilodrostat blocks the enzymes 11β‑hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2). These enzymes are required for the final steps of cortisol and aldosterone synthesis. Inhibition reduces cortisol output, addressing the hormonal imbalance in Cushing's disease.

The dosage of Isturisa is individualized. A qualified prescriber determines the starting dose and any adjustments based on the patient’s cortisol levels, clinical response, and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for osilodrostat in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Isturisa (osilodrostat) directly inhibits cortisol synthesis, whereas other options such as ketoconazole or metyrapone also target steroidogenesis but differ in enzyme selectivity and side‑effect profiles. Pituitary surgery remains first‑line, and medical therapy is added when surgery is not feasible or fails.

Isturisa tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Isturisa is taken orally as a tablet. The exact timing and whether it is taken with food depend on the prescriber’s instructions. Patients should swallow the tablet whole with water and not split or crush it unless directed.

Serious risks include adrenal insufficiency, severe hypertension, hypokalemia, QT interval prolongation, and potential liver injury. Patients should be monitored regularly for these events, and any signs such as extreme fatigue, dizziness, or abnormal heart rhythm should prompt immediate medical evaluation.

Isturisa is contraindicated in patients with known hypersensitivity to osilodrostat or any tablet excipients. It should be used with caution in individuals with uncontrolled hypertension, significant electrolyte disturbances, or severe liver disease, and it is not recommended for pregnant women unless absolutely necessary.